Loading
Life sciences · Journal article
International Journal of Drug Delivery Technology · October 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Breast cancer is the second most prevalent malignancy and the leading cause of cancer-related mortality among women worldwide, highlighting the need for novel therapeutic agents.Natural products, particularly plant-derived phytochemicals, are promising candidates for anticancer drug discovery.This study employed an integrated in silico and in vitro approach to evaluate the anticancer potential of Simarouba glauca phytoconstituents targeting estrogen receptor alpha (ERα-3ERT), progesterone receptor (PR-1SQN), and HER2/neu (3PP0).Molecular docking using the Glide module of Schrödinger Maestro assessed binding affinities and interactions, followed by molecular dynamics simulations for stability analysis.Drug-likeness and pharmacokinetic properties were predicted using QikProp.Docking results identified PR as the most favorable target, with glaucarbolone, amarolide, and ailanthone demonstrating strong binding affinities (-12.095,-10.868, and -10.868 kcal/mol, respectively) and the interaction throughpolar residues such as ASN719, LEU718, THR894 and GLN725 were observed.In contrast, moderate binding affinities were observed against ERα, with glaucarubinone through THR347 and LEU536 and dehydroglaucarubinone toward HER2/neu (-6.017 kcal/mol) via interactions with SER728, THR862, and ASP863.Molecular dynamics simulations confirmed the structural stability of the top-ranked glaucarbolone-PR complex, supporting its favorable binding mode.ADMET analysis revealed that all evaluated quassinoids complied with Lipinski's rule of five, and three exhibited favorable pharmacokinetic profiles.In vitro anti-proliferative studies demonstrated that Simarouba glauca leaf extract exhibits stronger activity against hormone-dependent breast cancer cells (MCF-7) compared to triple-negative cells (MDA-MB-231), with lower IC₅₀ values (61.56 and 155.06 µg/mL, respectively).These findings highlight the potential of Simarouba glauca phytochemicals, particularly PR-targeting phytochemical compounds, as promising lead candidates for breast cancer therapy and underscore the effectiveness of integrated in silico approaches in early-stage anticancer drug discovery.